Treatment Clinical Trials for Breast Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for breast cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 476-500 of 500
< Previous 1 ... 18 19 20

  • Capecitabine and Radiation Therapy after Surgery in Treating Patients with Non-Metastatic Invasive Breast cancer

    This phase I trial studies how well capecitabine and radiation therapy after surgery work in treating patients with invasive breast cancer that has not spread to other places in the body. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving capecitabine and radiation therapy together may kill more tumor cells in patients with invasive breast cancer compared to capecitabine or radiation therapy alone.
    Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee

  • Olaparib, Palbociclib, and Fulvestrant in Treating Patients with BRCA Mutation-Associated, Hormone Receptor-Positive, and HER2-Negative Advanced Breast Cancer

    This phase I / II trial studies the best dose and side effects of palbociclib when given together with olaparib and fulvestrant, and to see how well they work in treating patients with BRCA mutation-associated, hormone receptor-positive, HER2-negative breast cancer that has spread from its original site of growth to nearby tissues or lymph nodes and cannot be removed by surgery, or has spread to other places in the body (advanced). Palbociclib and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Anti-hormone therapy consisting of fulvestrant may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation. This trial studies the effectiveness of the combination of palbociclib, olaparib and fulvestrant.
    Location: 2 locations

  • Talimogene Laherparepvec with Paclitaxel or Endocrine Therapy in Treating Participants with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer

    This phase Ib trials studies the side effects and how well talimogene laherparepvec works when given together with paclitaxel or endocrine therapy in treating participants with breast cancer that does not express the human epidermal growth factor receptor 2 (HER2) protein and has spread to other places in the body, cannot be removed by surgery, or has come back after. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may attack specific tumor cells and stop them from growing or kill them. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Estrogen can cause the growth of breast cancer cells. Drugs used as endocrine therapy, such as letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, may lessen the amount of estrogen made by the body or may may stop the growth of tumor cells by blocking estrogen from connecting to the cancer cells. Giving talimogene laherparepvec with paclitaxel or endocrine therapy may work better in treating participants with HER2-negative breast cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients with Breast Cancer

    This pilot clinical trial will evaluate whether the SCOUT reflector can be used to tag abnormal lymph nodes in patients with breast cancer prior to chemotherapy for targeted removal at the time of surgery. The SCOUT localization system with the SAVI reflector is non-radioactive and completely internal so can be placed into an abnormal lymph node prior to chemotherapy treatment, which theoretically will allow easier identification and therefore more reliable targeting of the abnormal lymph node for surgical removal.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Stellate Ganglion Blockade with Bupivacaine Hydrochloride in Reducing Hot Flashes in Hispanic Patients with Breast Cancer

    This phase II trial studies how well a stellate ganglion blockade with bupivacaine hydrochloride works in reducing hot flashes in Hispanic patients with breast cancer. A stellate ganglion blockade using bupivacaine hydrochloride (a local anesthetic used to block signals at nerve endings) may help to reduce the number and severity of hot flashes in Hispanic patients with breast cancer.
    Location: Northwestern University, Chicago, Illinois

  • Paclitaxel and Carboplatin before Surgery in Treating Nigerian Women with Stage IIA-IIIC Breast Cancer

    This phase II trial studies how well paclitaxel works with carboplatin before surgery in treating Nigerian women with stage IIA-IIIC breast cancer before surgery. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois

  • Standard of Care Therapy with or without Stereotactic Radiosurgery and / or Surgery in Treating Patients with Limited Metastatic Breast Cancer

    This randomized phase II / III trial studies how well standard of care therapy with stereotactic radiosurgery and / or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and / or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may be able to effectively remove the metastatic tumor cells. It is not yet known whether standard of care therapy is more effective with stereotactic radiosurgery and / or surgery in treating limited metastatic breast cancer.
    Location: 131 locations

  • Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery

    This randomized phase III trial studies lymph node dissection and radiation therapy to see how well it works compared to radiation therapy alone in treating patients with breast cancer previously treated with chemotherapy and surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x rays or protons to kill tumor cells. It is not yet known if radiation therapy works better alone or with lymph node dissection in treating patients with breast cancer previously treated with chemotherapy and surgery.
    Location: 990 locations

  • MRI-Guided Accelerated Partial Breast Irradiation in Treating Patients with Early Breast Cancer

    This phase II trial studies how well magnetic resonance imaging (MRI)-guided accelerated partial breast irradiation works in treating patients with breast cancer that is early in its growth and may not have spread to other parts of the body. Accelerated partial breast irradiation is a localized form of radiation delivered after surgery to the part of the breast where the tumor was removed only, which may spare the remaining healthy breast tissue. MRI is an imaging technique used to form pictures of the area of treatment to allow for the treatment to focus more on the tumor site. This study may help researchers determine if giving MRI-guided accelerated partial breast irradiation after surgery reduces the side effects that can occur to surrounding healthy tissue.
    Location: University of Wisconsin Hospital and Clinics, Madison, Wisconsin

  • Molecular Profile of Breast Cancer in Ugandan Patients with Stage IIB-III Breast Cancer

    This phase I trials studies the molecular profile of breast cancer in Ugandan patients with stage IIB-III breast cancer. Creating a molecular profile of breast cancer my help doctors learn more about biological factors associated with breast cancer in Ugandan patients with as well as measure the benefits of locally available diagnostic studies and the possibility of providing treatment via oral medication.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

    This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.
    Location: Mayo Clinic, Rochester, Minnesota

  • Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (“GLACIER”)

    This phase I / II trial studies the side effects of hydroxychloroquine with or without gedatolisib and to see how well they work in preventing cancer from coming back in patients with stage I-III breast cancer. Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Gedatolisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine alone or in combination with gedatolisib may reduce or eliminate breast cancer cells that have spread to the bone marrow in patients with stage I-III breast cancer.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Chemotherapy with or without Metformin Hydrochloride in Treating Patients with HER2 Positive Breast Cancer That Can Be Removed by Surgery

    This randomized phase II trial studies how well chemotherapy with or without metformin hydrochloride work in treating patients with HER2 positive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, pertuzumab, and pegfilgrastim, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may prevent or lower risk of breast cancer and decrease cancer cells, lower risk of cancer spreading. It is not yet known whether giving metformin hydrochloride with chemotherapy will work better in treating patients with breast cancer.
    Location: 6 locations

  • Pembrolizumab and Mifepristone in Treating Patients with Metastatic or Locally Advanced and Unresectable HER2-Negative Breast Cancer

    This phase II trial studies how well pembrolizumab and mifepristone works in treating patients with HER2-negative breast cancer that has spread to other places in the body, or to nearby tissues or lymph nodes and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Hormone therapy using mifepristone may fight breast cancer by lowering the amount of progesterone and glucocorticoid the body makes. Giving pembrolizumab and mifepristone may work better in treating patients with HER2-negative breast cancer.
    Location: 2 locations

  • Copanlisib, Letrozole, and Palbociclib in Treating Patients with Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

    This phase I / II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer. Copanlisib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving copanlisib, letrozole, and palbociclib may work better in treating patients with breast cancer.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Tucatinib, Letrozole, and Palbociclib in Treating Patients with Advanced or Metastatic Hormone Receptor and HER2 Positive Breast Cancer That Cannot Be Removed by Surgery

    This phase Ib / II trial studies the side effects of tucatinib, letrozole, and palbociclib and how well they work in treating patients with in hormone receptor and HER2 positive breast cancer that has spread to other places in the body and cannot be removed by surgery. Tucatinib, letrozole, and palbociclib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 6 locations

  • Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer

    This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.
    Location: Mayo Clinic in Arizona, Scottsdale, Arizona

  • Carboplatin and Paclitaxel with or without Atezolizumab before Surgery in Treating Patients with Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

    This phase II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
    Location: 14 locations

  • 18F-FBnTP Positron Emission Mammography in Detecting Breast Cancer in Patients with Intraductal Breast Cancer

    This phase I trial studies how well 18F-FBnTP positron emission mammography works in detecting breast cancer in patients with intraductal breast cancer. 18F-FBnTP positron emission mammography may detect may detect breast lesions with better sensitivity and better specificity.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

    This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
    Location: See Clinical Trials.gov

  • Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients with Recurrent Stage IIIC-IV Breast Cancer

    This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back. Drugs used in chemotherapy, such as eribulin mesylate and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 31 locations

  • Vaccine Therapy in Treating Patients with Stage IB-IIIA Breast Cancer

    This phase II clinical trial studies the side effects of vaccine therapy in treating patients with stage IB-IIIA breast cancer. Vaccines made from peptides and immune stimulant may help the body build an effective immune response to kill tumor cells.
    Location: See Clinical Trials.gov

  • Accelerated Partial Breast Irradiation Using Proton Beam Scanning before Surgery in Treating Patients with Triple-Negative Breast Cancer

    This pilot clinical trial studies the side effects of accelerated partial breast irradiation using proton beam scanning and to see how well it works before surgery in treating patients with triple-negative breast cancer. Accelerated partial breast irradiation using proton beam scanning administered in higher doses over a shorter time period may help stop cancer from growing while protecting normal tissue cells.
    Location: See Clinical Trials.gov

  • Nivolumab and Cabozantinib in Treating Patients with Metastatic Triple-Negative Breast Cancer

    This phase II trial studies how well nivolumab and cabozantinib work in treating patients with triple negative breast cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib may work better in treating patients with triple negative breast cancer.
    Location: See Clinical Trials.gov

  • Buparlisib or Alpelisib and Olaparib in Treating Patients with Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

    This phase I trial studies the side effects and best dose of buparlisib or alpelisib when given together with olaparib in treating patients with triple negative breast cancer or high grade serous ovarian cancer that has come back (recurrent). Buparlisib, alpelisib, and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: See Clinical Trials.gov


< Previous 1 ... 18 19 20